🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in the Netherlands / NCT05062707
Recruiting Observational

Early Ageing During Therapy in AYA Cancer Patients

NCT05062707 · tracked via the Priya Life Science Netherlands tracker
Phase
Observational
Started
2022-02-10
Last updated
2025-05-13

Condition(s) studied

CancerLeukemiaHodgkin LymphomaTesticular CancerOsteosarcomaEwing SarcomaBreast CancerCervical Cancer

Investigational drug(s) / intervention(s)

Blood sampling

Blood sampling: Study measurements will be performed twice and consist of blood withdrawal and physical examination (weight, height, waist-hip ratio, and blood pressure).

Study summary

Longitudinal cohort study; measurements before start of systemic therapy and one year later.

Eligibility

Sex
ALL
Min age
18 Years
Max age
39 Years
Healthy volunteers
No
Inclusion Criteria: * Aged 18-39 years at cancer diagnosis * Having a histologically and/or cytologically confirmed cancer diagnosis, including leukemia, (non-)Hodgkin lymphoma, testicular cancer, osteosarcoma, Ewing sarcoma, breast cancer, and cervical cancer. * Scheduled to start systemic therapy with curative intent. Allowed treatments (concurrent or sequential) are: surgery, radiotherapy, chemotherapy, antibodies. Exclusion Criteria: * patients who are not able to understand the patient information letter and informed consent form * patients who will be treated with immune checkpoint inhibitors or targeted therapy with inhibitors of angiogenesis * patients who have been treated with systemic therapy or radiotherapy for a previous malignancy (exceptions: in situ carcinoma of the cervix or uterus and adequately treated basal and squamous cell carcinoma of the skin).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University Medical Center Groningen Groningen Netherlands Recruiting

More University Medical Center Groningen trials in the Netherlands

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05062707 on ClinicalTrials.gov ↗ ← All trials in the Netherlands